Paracetamol (acetaminophen)

Section: 5. Medicines for neurological disorders > 5.1. Medicines for central nervous system disorders > 5.1.5. Medicines for headache disorders > 5.1.5.1. Medicines for acute migraine attacks

EMLc | Codes ATC: N02BE01

Indication	Migraine Code ICD11: 8A80.Z
INN	Paracetamol
Type de médicament	Chemical agent
Type de liste	Liste de base
Additional notes	*The presence of both 120 mg/5 mL and 125mg/5mL oral liquid strengths on the same market would cause confusion in prescribing and dispensing and should be avoided
Formulations	**Oral > Liquid:** 125 mg per 5 mL (EMLc) ; 120 mg per 5 mL (EMLc) ; 250 mg per 5 mL (EMLc) **Local > Rectal > Suppository:** 250 mg (EMLc) **Oral > Solid > dispersible tablet:** 100 mg (EMLc) ; 250 mg (EMLc) **Oral > Solid > tablet:** 250 mg ; 325 mg ; 500 mg
Historique des statuts LME	Ajouté pour la première fois en 1987 (TRS 770) Modifié en 2007 (TRS 950) Modifié en 2017 (TRS 1006) Modifié en 2023 (TRS 1049)
Sexe	Tous
Âge	Aussi recommandé pour les enfants
Équivalence thérapeutique	La recommandation concerne ce médicament spécifique
Renseignements sur le brevet	Patents have expired in most jurisdictions Lire la suite sur les brevets.
Wikipédia	Paracetamol (acetaminophen)
DrugBank	Paracetamol (Acetaminophen)

Résumé des preuves et recommandation du comité d'experts

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the deletion of the 100 mg tablet formulation from the EML and EMLc - strengths of paracetamol tablets should specified rather than given in a range - the addition of a 250 mg strength suppository formulation to the EMLc - the addition of paracetamol dispersible tablets (100 mg and 250 mg) to the EMLc - the addition of 250 mg/5mL strength oral liquid formulation to the EMLc - the addition of a note stating "the presence of both 120 mg/5 mL and 125mg/5mL oral liquid strengths on the same market would cause confusion in prescribing and dispensing and should be avoided"